Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

MelanomaHead and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

DRUG

Avelumab

Anti-PDL1 antibody

Trial Locations (2)

Memorial Sloan Kettering Cancer Center, New York

Docrates Cancer Center, Helsinki

All Listed Sponsors

lead

TILT Biotherapeutics Ltd.

INDUSTRY